Cadrenal Therapeutics, Inc.·4

Dec 31, 4:05 PM ET

Szot Matthew K 4

4 · Cadrenal Therapeutics, Inc. · Filed Dec 31, 2025

Insider Transaction Report

Form 4
Period: 2025-12-29
Szot Matthew K
Chief Financial Officer
Transactions
  • Sale

    Common Stock

    2025-12-29$6.97/sh9,933$69,2330 total
Footnotes (1)
  • [F1]Represents shares of the Issuer's common stock sold by the Reporting Person in accordance with a Rule 10b5-1 trading arrangement adopted by the Reporting Person on September 18, 2025, in multiple transactions at prices ranging from $6.83 through $7.37, inclusive, having a weighted average price as shown in column 4 of $6.97. The Reporting Person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Documents

1 file
  • 4
    ownership.xmlPrimary